1 Haute Autorité de Santé: Prise en charge diagnostique des neuropathies périphériques (polyneuropathies et mononeuropathies multiples). http://www.has-sante.fr. 2007.
2 Deutsche Gesellschaft für Neurologie: Erkrankungen peripherer Nerven. Leitlinien für Diagnostik und Therapie in der Neurologie: http://www.dgn.org/leitlinien; 2015.
3 Bouhassira D, Attal N. Diagnosis and assessment of neuropathic pain: the saga of clinical tools. Pain. 2011;152:74–83.
4 EFNS/PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy-First Revision. J Peripher Nerv Syst. 2010;15:1–9.
5 Gibbons CH. Small fiber neuropathies. Continuum (Minneap Minn). 2014;20:1398–412.
6 Antoine JC, Boutahar N, Lassabliere F, Reynaud E, Ferraud K, Rogemond V, et al. Antifibroblast growth factor receptor 3 antibodies identify a subgroup of patients with sensory neuropathy. J Neurol Neurosurg Psychiatry. 2015;86:1347–55.
7 Diezi M, Buclin T, Kuntzer T. Toxic and drug-induced peripheral neuropathies: updates on causes, mechanisms and management. Curr Opin Neurology. 2013;26:481–8.
8 Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.
Curr Opin Neurology. 2016;29 Suppl 1:14–26.
9 Lally L, Spiera R. B-cell-targeted therapy in systemic vasculitis. Curr Opin Rheumatol. 2016;28:15–20.
10 Uncini A, Kuwabara S. Nodopathies of the peripheral nerve: an emerging concept. J Neurol Neurosurg Psychiatry. 2015;86:1186–95.
11 Rajabally YA. Novel Therapeutic Avenues for Chronic Inflammatory Demyelinating Polyneuropathy: The Difficulties of Disease Diversity. EBioMedicine. 2016;6:12–3.